公司简介
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also ...
关联新闻
- A failed trial for a heart drug casts shadow over rivals developing similar therapies
The full data from the closely watched clinical trial showed that the drug had no cardiovascular benefit even though it reduced Lp(a) levels.
- Ionis Slashes Key Drug Revenue Outlook by 50%, Overshadowing Otherwise Solid Earnings
Shares of Ionis Pharmaceuticals sink after it slashes full-year revenue guidance for one of its flagship drugs.
- Otsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Otsuka Pharmaceutical and Ionis Pharmaceuticals said on Tuesday their experimental drug met the main goal of a late-stage study in patients with a rare inherited form of amyotrophic lateral sclerosi...
- Ionis, Novartis' key experimental heart drug fails in late-stage trial
Ionis Pharmaceuticals and partner Novartis' experimental drug to lower high levels of a cholesterol-carrying particle in heart patients failed in a late-stage trial, the companies said on Friday.
- This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
- US FDA approves Ionis Pharma's therapy to treat rare brain disorder
The U.S. FDA on Thursday approved Ionis Pharmaceuticals' therapy to treat a rare disease that affects the brain's white matter, making it the first treatment to get the nod for the genetic disorde...